Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Purdue Frederick’s Gentlax

This article was originally published in The Tan Sheet

Executive Summary

Marketing support for new bisacodyl USP 5 mg stimulant laxative includes FSI that dropped Dec. 8, cable and network TV ads, rebates, physician samples and direct mail, Purdue says. Ad agency is Della Femina Rothschild Jeary & Partners (New York). Purdue previously sold Gentlax granules containing senna but discontinued the product several years ago. Senna is a Category III ingredient under the OTC laxatives tentative final monograph; bisacodyl has been reclassified as Category I. Gentlax began shipping Nov. 1; packages of 20 and 100 tablets carry wholesaler prices of $2.96 and $12.25, respectively. Purdue, other companies are sponsoring carcinogenicity research on senna. Firm plans to submit data to FDA in March supporting Category I status for senna, which is found in Purdue's Senokot laxatives...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094918

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel